JP2016518334A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518334A5
JP2016518334A5 JP2016502514A JP2016502514A JP2016518334A5 JP 2016518334 A5 JP2016518334 A5 JP 2016518334A5 JP 2016502514 A JP2016502514 A JP 2016502514A JP 2016502514 A JP2016502514 A JP 2016502514A JP 2016518334 A5 JP2016518334 A5 JP 2016518334A5
Authority
JP
Japan
Prior art keywords
alkyl
haloalkyl
cycloalkyl
independently
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502514A
Other languages
English (en)
Japanese (ja)
Other versions
JP6456909B2 (ja
JP2016518334A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/027679 external-priority patent/WO2014152738A1/en
Publication of JP2016518334A publication Critical patent/JP2016518334A/ja
Publication of JP2016518334A5 publication Critical patent/JP2016518334A5/ja
Application granted granted Critical
Publication of JP6456909B2 publication Critical patent/JP6456909B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502514A 2013-03-15 2014-03-14 Lxr調節因子 Expired - Fee Related JP6456909B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787422P 2013-03-15 2013-03-15
US61/787,422 2013-03-15
PCT/US2014/027679 WO2014152738A1 (en) 2013-03-15 2014-03-14 Lxr modulators

Publications (3)

Publication Number Publication Date
JP2016518334A JP2016518334A (ja) 2016-06-23
JP2016518334A5 true JP2016518334A5 (https=) 2017-04-20
JP6456909B2 JP6456909B2 (ja) 2019-01-23

Family

ID=51581300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502514A Expired - Fee Related JP6456909B2 (ja) 2013-03-15 2014-03-14 Lxr調節因子

Country Status (6)

Country Link
US (1) US9751869B2 (https=)
EP (1) EP2967073B9 (https=)
JP (1) JP6456909B2 (https=)
CN (1) CN105188380B (https=)
ES (1) ES2694001T3 (https=)
WO (1) WO2014152738A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209039B (zh) 2013-03-15 2018-06-22 百时美施贵宝公司 Lxr调节剂
ITUA20164199A1 (it) * 2016-06-08 2017-12-08 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Modulatori di soce compisizioni e relativi usi
WO2018091389A1 (en) 2016-11-17 2018-05-24 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulphur containing substituents
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN113457708B (zh) * 2021-06-30 2023-10-20 常州大学 CoN@C多孔材料及其制备方法以及在芳香族腈类化合物的合成中的应用
KR20250030474A (ko) * 2022-06-10 2025-03-05 시오나 테라퓨틱스 인크. 화합물, 조성물 및 이의 사용 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE252290T1 (de) 1986-06-10 1988-06-09 Chiesi Farmaceutici S.P.A., Parma Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5908852A (en) 1994-11-14 1999-06-01 G. D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
CN100513570C (zh) 1999-06-18 2009-07-15 Cv治疗公司 结合框运输蛋白abc1的调节作用
WO2001082917A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Treatment of hypertriglyceridemia and other conditions using lxr modulators
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7247735B2 (en) 2002-07-26 2007-07-24 Infineon Technologies Ag Octupolar molecules used as organic semiconductors
AU2003293376A1 (en) 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
MY142651A (en) 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
CA2522476A1 (en) 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
US8318760B2 (en) * 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Lxr 및 fxr 조절자
KR101676704B1 (ko) 2009-05-28 2016-11-16 엑셀리시스 페이턴트 컴퍼니 엘엘씨 Lxr 조절자
SG10201607345YA (en) * 2012-03-02 2016-11-29 Ralexar Therapeutics Inc Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
CN105209039B (zh) 2013-03-15 2018-06-22 百时美施贵宝公司 Lxr调节剂

Similar Documents

Publication Publication Date Title
JP2016518334A5 (https=)
JP2016513730A5 (https=)
JP2014507455A5 (https=)
JP2017513894A5 (https=)
JP2013529210A5 (https=)
JP2016516043A5 (https=)
JP2016500063A5 (https=)
RU2017131875A (ru) Трехъядерные соединения и их применение в медицине
JP2018534329A5 (https=)
JP2014506907A5 (https=)
JP2017514856A5 (https=)
JP2017530959A5 (https=)
JP2016531126A5 (https=)
JP2016528273A5 (https=)
JP2011529049A5 (https=)
CY1118135T1 (el) Παραγωγα 2-(φαινυλο ή πυριδ-3-υλο) αμινοπυριμιδινης ως ρυθμιστες κινασης lrrk2 για τη θεραπευτικη αντιμετωπιση της νοσου του parkinson
JP2016506962A5 (https=)
JP2014511891A5 (https=)
JP2016526576A5 (https=)
JP2016506960A5 (https=)
JP2016522266A5 (https=)
JP2016535772A5 (https=)
JP2013542261A5 (https=)
FI3848027T3 (fi) Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita
JP2015517579A5 (https=)